SC issues notice on PIL seeking action against doctors who do not prescribe generic medicines

New Delhi : The Supreme Court on Friday issued notice on a PIL seeking disciplinary actions against doctors who fail to prescribe generic medicines.

A bench comprising Chief Justice of India D.Y. Chandrachud, Justices J.B. Pardiwala and Manoj Misra sought response from the Centre, all state governments, Ethics and Medical Registration Board (erstwhile Medical Council of India) and others in the matter.

Advocate K.C. Jain, the petitioner, apprised the bench that regulations emphasizing the importance of prescribing generic medicines, which were notified back in 2002, remain largely unimplemented in practice.

He said that the Indian Medical Council (Professional Conduct, Etiquette, and Ethics) Regulations, 2002, which highlight the significance of prescribing drugs by their generic names, exist solely within legal frameworks.

The plea said that affordability of medicines is a vital factor that contributes to effective healthcare delivery and the realization of the ‘right to health’.

“Generic drugs, which have the same active ingredients as their branded counterparts but are not marketed under a specific brand name, are often significantly cheaper. The prices of generic medicines (off-patented) can be 50 per cent to 90 per cent lower than those of branded medicines,” stated the petition.

It sought directions to the National Pharmaceuticals Pricing Authority to fix the Maximum Retail Price (MRP) of Non Scheduled formulations and off-patented generic medicines.

“By prescribing generic drugs, healthcare professionals can help alleviate the financial burden on patients and facilitate their access to vital medications,” the plea said.

Related Posts

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

Milan: CPHI Milan 2026, one of the pharmaceutical industry’s largest global events, has launched four specialist zones designed to connect pharmaceutical companies with the technologies, services and expertise shaping the…

Lilly takes 6 companies to court for selling retatrutide knockoffs

Washington: Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. But the buzz surrounding the effectiveness of the compound—commonly known as triple-G—has already triggered a…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

Lilly takes 6 companies to court for selling retatrutide knockoffs

Lilly takes 6 companies to court for selling retatrutide knockoffs

FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch